LY294002

目录号：S1105 别名： SF 1101, NSC 697286

LY294002 Chemical Structure

Molecular Weight(MW): 307.34

LY294002 是首个合成的已知抑制PI3Kα/δ/β的小分子，在无细胞测定中IC50分别为 0.5 μM/0.57 μM/0.97 μM；在溶液中比在Wortmannin中稳定，也能够阻断自噬体的形成。它不仅能够结合class I PI3Ks和其他PI3K相关的激酶，还能够结合一些与PI3K家族无关的新型靶点。

规格 价格 库存 购买数量  
In DMSO RMB 1570.11 现货
RMB 1188.16 现货
RMB 2196.01 现货
RMB 6298.74 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck该产品发表文献271篇：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 LY294002 是首个合成的已知抑制PI3Kα/δ/β的小分子，在无细胞测定中IC50分别为 0.5 μM/0.57 μM/0.97 μM；在溶液中比在Wortmannin中稳定，也能够阻断自噬体的形成。它不仅能够结合class I PI3Ks和其他PI3K相关的激酶，还能够结合一些与PI3K家族无关的新型靶点。
特性 LY294002是选择性的, 可渗透细胞的特定PI3K抑制剂，可作用于酶的ATP结合位点，且抑制自体吞噬的螯合作用。
靶点
p110α [1]
(Cell-free assay)		 p110δ [1]
(Cell-free assay)		 p110β [1]
(Cell-free assay)		 DNA-PK [6]
(Cell-free)
0.5 μM 0.57 μM 0.97 μM 1.4 μM
体外研究

LY294002是一种非特异性抑制剂，除了class I PI3Ks，它同样还能抑制其他类型PI3Ks、mTOR、DNA-PK以及其他蛋白激酶，如CK2和Pim-1[5]。LY294002使Akt/PKB失活,因此抑制细胞增殖和诱导细胞凋亡。 LY294002作用于结肠癌细胞系，使磷酸化Akt (Ser473)的表达下降， 明显抑制生长和诱导凋亡。[2] LY294002作用于肿瘤细胞，诱导明显的核固缩和减少细胞质体积。因此，在体外，LY294002明显抑制卵巢癌细胞增殖。LY294002诱导细胞停在G1期，导致几乎全部的黑色素瘤细胞增殖被抑制，部分MG-63 (骨肉瘤细胞系)增殖被抑制。LY294002作用于细胞周期的效果可用于研究PI3K激活通路和癌细胞周期之间关系。[3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 cells NIPmTpVE\WyuIHnueoF{cW:wIHHzd4F6 M3mxT|I1KGh? MkXOTY5pcWKrdHnvckBw\iCncHn0bIVtcWGuIHfyc5d1cCCoYXP0c5IucW6mdXPl[EBk\WyuIH3p[5JifGmxbjDv[kBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IIDy[U1qdmO3YnH0[YQh\m:{IEK0JIhzeyCkeTDj[YxtKGmwdnHzbY9vKGG|c3H5MEBKSzVyPUCuN|gh|ryPLh?= MnnCNlI5ODRzMEi=
Sf21 cells M2HTdmZ2dmO2aX;uJIF{e2G7 NWPKOVNkUW6qaXLpeIlwdiCxZjDtc5V{\SC5aXzkJJR6eGViUFmzT4FteGijIHX4dJJme3OnZDDpckBU\jJzIHPlcIx{KGOxLXX4dJJme3OrbnegUk11\XKvaX7hcEBJcXNvdHHn[4VlKGi3bXHuJJA5PWFidYPpcochVC2jbIDoZU1xcG:|cHjheIllgWyrbn;zbZRwdCC|dXLzeJJifGViYomgWGxEKGKjc3XkJJBpd3OyaH;yJIlu[WerbnesJGlEPTB;MD61JO69VQ>? NV3ac3ppOjJ3MkC2N|A>
Sf21 cells NHPaVmJHfW6ldHnvckBie3OjeR?= MWLJcohq[mm2aX;uJI9nKG2xdYPlJJJm[2:vYnnuZY51KFCLM1vhcJBp[SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMucW6oZXP0[YQhW2Z{MTDj[YxteyxiSVO1NF0xNjVizszNMi=> M3TWblE6PzR6Mk[5
Sf9 cells MniySox2d3Knc3PlcpQheG:uYYLpfoF1cW:wIHHzd4F6 M1nlcmlvcGmkaYTpc44hd2ZiaIXtZY4hWEl|S3HsdIhiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZpkh\my3b4Lld4NmdnRicH;sZZJqgmG2aX;uJIF{e2G7LDDJR|UxRTBwNUWg{txONg>? M4XScFIyOTJzNkOx
THP1 cells NGDPcnVHfW6ldHnvckBie3OjeR?= MX\Jcohq[mm2aX;uJI9nKFOFRkGtbY5lfWOnZDDQT2IwSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDUTHAyKGOnbHzzMEBKSzVyPUGuNFEh|ryPLh?= MnX3NVY4QDl5NEK=
human PC3 cells MmTXSpVv[3Srb36gZZN{[Xl? NXjKNoFpOzBibXnu NGnROVhKdmirYnn0bY9vKG:oIGDJN2shcW5iaIXtZY4hWEN|IHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJGFMXCCyaH;zdIhwenmuYYTpc44h[XRic3XybY5mKDR5MzDh[pRmeiB|MDDtbY5{KGK7IFXMTXNCNCCLQ{WwQVEvO87:TT6= NIPlWlQzOzRzMECwOS=>
HeLa (human carcinoma) cells. NGS3fGdHfW6ldHnvckBie3OjeR?= M2fSemlvKH[rdILvJIlvcGmkaYTpc44hd2ZiRF7BMYRmeGWwZHXueEBxem:2ZXnuJItqdmG|ZTjEUmEuWEtrIH\yc40hUGWOYTCobJVu[W5iY3HyZ4lvd22jKTDj[YxteyxiSVO1NF0yNjRizszNMi=> M1TXSlE2PjV6OEew
THP1 cells MkjESpVv[3Srb36gZZN{[Xl? NWnPT3VVUW6qaXLpeIlwdiCxZjDNR3AyNWmwZIXj[YQhWEuEL1HreEBxcG:|cHjvdplt[XSrb36gbY4hXEiSMTDj[YxteyxiSVO1NF0yNjZ3IN88UU4> MVqxOlc5QTd2Mh?=
HeLa cells NH7hd2tHfW6ldHnvckBie3OjeR?= NVezU3RoUW6qaXLpeIlwdiCxZjDtWG9TKHC{b4TlbY4hcXOxbHH0[YQh\nKxbTDI[WxiKGOnbHzzMEBKSzVyPUKuOUDPxE1w NFXqcJcyPTZ3OEi3NC=>
human MCF7 cells M4HjS2N6fG:2b4jpZ:Kh[XO|YYm= NIr2fXJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGmwIIDy[ZNmdmOnIH;mJFIxKM7:TTDjbIxwem:zdXnu[UBjgSCVUlKgZZN{[XluIFfJOVA:Oi54MzFOwG0v M2OwTFE5PjlzOEm0
HeLa cells NE\td41HfW6ldHnvckBie3OjeR?= M1z5c2lvcGmkaYTpc44hd2ZiQWitO|UxOyCkaX7kbY5oKHSxIILlZ49u[mmwYX70JHBtczNiZYjwdoV{e2WmIHnuJGhmVGFiY3XscJMh[nliV3XzeIVzdiCkbH;0MEBKSzV;MzFOwG0v Mlz6NVcyOzV{NEi=
human MCF7 cells MWHDfZRwfG:6aXRCpIF{e2G7 MnP2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BqdiCycnXz[Y5k\SCxZjCxNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9N{4xQCEQvF2u MlPKNVg3QTF6OUS=
human MCF7 cells M2XPdGN6fG:2b4jpZ:Kh[XO|YYm= MlnFR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BjgSCVUlKgZZN{[XluIFfJQVMvOTZizszNMi=> NFzXb4EyQDZ7MUi5OC=>
human MDA-MB-231 cells NGXUZoJEgXSxdH;4bYPDqGG|c3H5 M{DwWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiMkCg{txOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4PhfUwhT0l;Mz6zNkDPxE1w NFXKU3oyQDZ7MUi5OC=>
human MDA-MB-231 cells NFfRe2pEgXSxdH;4bYPDqGG|c3H5 NVvndI5HS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BqdiCycnXz[Y5k\SCxZjCxNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9OE4{PSEQvF2u MUWxPFY6OTh7NB?=
human MDA-MB-468 cells MVXDfZRwfG:6aXRCpIF{e2G7 NW[zdGFRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZnwxIxiSVO1NF01Njd4IN88UU4> MnfPNVg3QTF6OUS=
human HCT116 cells MnHYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHvLbGo1QCCq MoDKS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJHBKO0ujbIDoZUBJOTB2N2KgcZV1[W62IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PS5|IN88US=> MlvnNlIzOTJ5MkG=
human HCT116 cells MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEDDS5A1QCCq M4rIPWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVUvQCEQvF2u Mk\TNlIzOTJ5MkG=
HeLa cells Mn;uRolv\GmwZzDh[oZqdmm2eTDhd5NigQ>? MYrCbY5lcW6pIHHm[olvcXS7IH\vdkBRUTNva3nuZZNmKGm|b3zheIVlKG[{b32gTIVN[SClZXzsd{whU2l;NjFOwG0> NGC5PWMyPTZ3OEi3NC=>
human HCT116 cells MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NITRSFc1QCCq Mk[5S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJHBKO0ujbIDoZUBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPU[uO{DPxE1w M{nNcFIzOjF{N{Kx
MDA-MB-231 cells M4DIZWN6fG:2b4jpZ:Kh[XO|YYm= NUHnR3F[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:Pi55MTFOwG0v NE\ybY8yQDZ7MUi5OC=>
Sf9 cells NUfJfYZkTnWwY4Tpc44h[XO|YYm= NWryS3NZUW6qaXLpeIlwdiCxZjDDT|Ih\XiycnXzd4VlKGmwIGPmPUBk\WyuczygTWM2OD14Lkmg{txONg>? NGnaUXoyQDN{MUexOi=>
human U87MG cells MnzVSpVv[3Srb36gZZN{[Xl? NInVWpVKdmirYnn0bY9vKG:oIFfTT|Mu[mW2YTDpckBpfW2jbjDVPFdOTyClZXzsd{BjgSCHTFnTRUwhUUN3ME24MlEh|ryPLh?= NGDUPHoyQDN2NU[wPS=>
human MDA-MB-468 cells MYTDfZRwfG:6aXRCpIF{e2G7 M17McGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiMUCgeW0h[2iub4LvdZVqdmViYomgV3JDKGG|c3H5MEBIUTVyPUiuNkDPxE1w MU[xPFY6OTh7NB?=
human A375 cells M1;2d3Bzd2yrZnXyZZRqd25iYYPzZZk> MkT2OFYhcA>? M2O2TmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUO3OUBk\WyuczDh[pRmeiB2NjDodpMtKEmFNUC9PE41KM7:TT6= MXWxO|A1QTJ2OB?=
human A375 cells Mm\uVJJwdGmoZYLheIlwdiCjc4PhfS=> MWfJcohq[mm2aX;uJI9nKHOncoXtMYlv\HWlZXSgdJJwdGmoZYLheIlwdiCxZjDoeY1idiCDM{e1JINmdGy|LDDJR|UxRThwNDFOwG0v MlqzNVc3ODF5M{m=
human HL60 cells MYrDfZRwfG:6aXRCpIF{e2G7 MWq3NkBp M3z3V2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME25Mlk1KM7:TT6= NHXTSJEzOjR6MEi1NS=>
mouse Raw264 macrophage MVLGeY5kfGmxbjDhd5NigQ>? NYT3d29uUW6qaXLpeIlwdiCxZjDDOYEudWWmaXH0[YQhWEuEL1HreEBxcG:|cHjvdplt[XSrb36gbY4hdW:3c3WgVoF4OjZ2IH3hZ5JweGijZ3WsJGlEPTB;MUCg{txONg>? MWOxOlc5QTd2Mh?=
Sf9 cells M{L3fWZ2dmO2aX;uJIF{e2G7 MYrJcohq[mm2aX;uJI9nKEircz30ZYdo\WRiYn;2bY5mKFCLM1ug[ZhxemW|c3XkJIlvKFOoOTDj[YxteyxiSVO1NF0yOCEQvF2u Ml23NVA6QTh|NUG=
human MDA-MB-468 cells MWXDfZRwfG:6aXRCpIF{e2G7 M3;BWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZpkhW1KEIHHzd4F6NCCLQ{WwQVExNjRizszNMi=> Mo\yNVg3QTF6OUS=
human PC3 cell NYLsbpBYWHKxbHnm[ZJifGmxbjDhd5NigQ>? NVPNeZFsPzJiaB?= MVnJcohq[mm2aX;uJI9nKGi3bXHuJHBEOyClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KHOyZXP0do9xcG:2b33leJJq[yCjbnHsfZNqeyxiSVO1NF0yOi5zIN88UU4> MmGyNlM1OTByMEW=
human HL60 cells NED2V3JRem:uaX\ldoF1cW:wIHHzd4F6 MUO3NkBp NI\KO3RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhZpNwemKjbnPlJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MUiuOFMh|ryPLh?= Mm\LNlU3QTN5OEe=
human BT474 cell MmrTVJJwdGmoZYLheIlwdiCjc4PhfS=> MYm3NkBp M{jE[mlvcGmkaYTpc44hd2ZiaIXtZY4hSlR2N{SgZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDzdIVkfHKxcHjveI9u\XS{aXOgZY5idHm|aYRvwKwhUUN3ME2yNE44KM7:TT6= M2HMU|I{PDFyMEC1
THP1 cells MXHGeY5kfGmxbjDhd5NigQ>? MUXJcohq[mm2aX;uJI9nKE2FUEGtbY5lfWOnZDDjbIVud3SjeHnzJI9nKFSKUEGgZ4VtdHNuIFnDOVA:OzdizszNMi=> MnXNNVY4QDl5NEK=
human 184B5 cells NGqwNXdEgXSxdH;4bYPDqGG|c3H5 MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxPFRDPSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OzlwM{eg{txONg>? M36wOVE5PjlzOEm0
human KB cells MXnDfZRwfG:6aXRCpIF{e2G7 MYe3NkBp NEXt[5ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUS0Mlc3KM7:TT6= NXvqPFd[OjF7NEWyOVA>
mouse RAW264.7 cells MWfGeY5kfGmxbjDhd5NigQ>? NF7jSYIzPSEQvF2= NF7v[HMzOCCq M{LXNGlvcGmkaYTpc44hd2ZiUFmzT{9CU1RiaX6gcY92e2ViUlHXNlY1NjdiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBNWFNvaX7keYNm\CCrTl;TJJBzd3SnaX6g[ZhxemW|c3nvckBifCB{NTFOwG0h[W[2ZYKgNlAhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? Ml;mNlQzQTl4MU[=
human A2780 cells NXL0[oNqSXCxcITvd4l{KGG|c3H5 MkXJNkDPxE1? M{C0[lEzKGh? NELLZXdKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJINqe3CuYYTpck1z\XOrc4ThcpQhcHWvYX6gRVI4QDBiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gdIhwe3Cqb4L5cIF1\WRiQXv0JIxmfmWuIHH0JFIhfU1iYX\0[ZIhOTJiaILzJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXNw MV2xO|Y5PDBzOB?=
human SW480 cells NFTR[2NHfW6ldHnvckBie3OjeR?= NHrkV5YzOCEQvF2= M2jYcFI1KGh? MVjE[YNz\WG|ZTDpckB{fXK4aY\pckBmgHC{ZYPzbY9vKGmwIHj1cYFvKFOZNEiwJINmdGy|IHH0JFIxKHWPIHHmeIVzKDJ2IHjyd{BjgSCrbX31co9jdG:2IHHuZYx6e2m| NECzVGIyPzR5Mkm2Ni=>
mouse mast cells NWXhOpU{TnWwY4Tpc44h[XO|YYm= NWjnPG56OjBizszN NWjoOZQzUW6qaXLpeIlwdiCxZjDTR2YucW6mdXPl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBud3W|ZTDtZZN1KGOnbHzzJIF1KDJyIN88US=> M1;pRlE3Pzh7N{Sy
human BJ cells NEXvfWZHfW6ldHnvckBie3OjeR?= Mm\CNlUh|ryP NYHXeY96OiCq MkHtTY5pcWKrdHnvckBw\iCSSUPLJJNq\26jbHnu[{BqdiCSRFfGMZN1cW23bHH0[YQhe2W{dX2gd5Rien[nZDDoeY1idiCESjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKHCuYYPtbYQhTUeIUD;QTEBld22jaX6gc4YhSWu2IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIGDIMWVITlBicnXkbZN1emmkdYTpc44hfG9icHzhd41iKG2nbXLyZY5mKGG2IEK1JJVOKHS{ZXH0[YQhOiCqcoOgZoVnd3KnIGDES2Yh[2ijbHzlcodmKGK7IHPvcoZw[2GuIH3pZ5Jwe2OxcIm= M3qxNVE3PzZ5MEi1
human IGROV1 cells MXTGeY5kfGmxbjDhd5NigQ>? MWCyOE81QCCq Mo\zTY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDoeY1idiCLR2LPWlEh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHzleoVtKGG2IEGgeI8hPSC2aX3ld{BKSzVyIHHmeIVzKDJ2IITvJFQ5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MUGyNVIyPjF3MR?=
human IGROV1 cells MoPzSpVv[3Srb36gZZN{[Xl? NHWyXIozPC92ODDo MlnwTY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDoeY1idiCLR2LPWlEh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iY4njcIlvKERzIHzleoVtKGG2IEGgeI8hPSC2aX3ld{BKSzVyIHHmeIVzKDJ2IITvJFQ5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MnvGNlEzOTZzNUG=
rat RBL2H3 cells NUHSblBSTnWwY4Tpc44h[XO|YYm= Ml7ETY5pcWKrdHnvckBw\iCDMkOxPFcucW6mdXPl[EBl\We{YX71cIF1cW:wIHnuJJJifCCUQlyyTFMh[2WubIO= M1nQU|E5OzJ6N{G2
human BJ cells NGHmWXVHfW6ldHnvckBie3OjeR?= MnfJNlUh|ryP Mly3NkBp NYPhT|M1SWO2aY\heIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFSqckOwPEBqdiCSRFfGMZN1cW23bHH0[YQhe2W{dX2gd5Rien[nZDDoeY1idiCESjDj[YxteyCjdDCyOUB2VSC2cnXheIVlKDJiaILzJIJm\m:{ZTDQSGdHKGOqYXzs[Y5o\SCkeTDpcY12dm:kbH;0eIlv\w>? NEXp[3QyPjd4N{C4OS=>
human HCT116 cells NES3TWJHfW6ldHnvckBie3OjeR?= MlPhNVAh|ryP M3PhfVExKG2rbh?= M1S0O2lvcGmkaYTpc44hd2ZiUFmzT4FteGijIHnuJIh2dWGwIFjDWFEyPiClZXzsd{B2e2mwZzDbN|JRZUGWUDDheEAyOCC3TTDh[pRmeiBzMDDtbY5{ MWOyNlIyOjd{MR?=
human HCT116 cells MnfLSpVv[3Srb36gZZN{[Xl? Ml;UNVAh|ryP MlniNVAhdWmw M4mwfWlvcGmkaYTpc44hd2ZiUFmzT4FteGijIFixNFQ4WiCvdYThcpQhcW5iaIXtZY4hUEOWMUG2JINmdGy|IIXzbY5oKFt|MmDdRXRRKGG2IEGwJJVOKGGodHXyJFExKG2rboO= NV\Ne3YxOjJ{MUK3NlE>
human HCT116 cells NFva[m1HfW6ldHnvckBie3OjeR?= MmjTNVAh|ryP MY\Jcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDheEAyOCC3TTDifUBqdW23bn;icI91KGGwYXz5d4l{ NVjofGt5OjJ{MUK3NlE>
human HCT116 cells MmTKSpVv[3Srb36gZZN{[Xl? MYKxNEDPxE1? MYfJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCKMUC0O3IhdXW2YX70JIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGG2IEGwJJVOKGK7IHntcZVvd2Kub4SgZY5idHm|aYO= NF;YUFczOjJzMkeyNS=>
human PC3 cells NX;hN5VHTnWwY4Tpc44h[XO|YYm= M1naOVUxKM7:TR?= NHvxZYE5KGh? MmfuTY5lfWO2aX;uJI9nKHB{MTDwdo91\WmwIHX4dJJme3Orb36gbY4hcHWvYX6gVGM{KGOnbHzzJIF1KDVyIIXNJIlv[3WkYYTl[EBnd3JiODDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbB?= NUm5dHpoOjJ7OUi0O|I>
human LNCAP cells NIX5T3NHfW6ldHnvckBie3OjeR?= NIDz[ogxNjFvM{Cg{txO NGTY[JI{OCCvaX6= NXzQZWZNUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGxPS0GSIHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCzNEBucW6|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? MVyyNlg{OjNzNh?=
human LNCAP cells NWPOSWh4TnWwY4Tpc44h[XO|YYm= NGDRdGsxNjFvM{Cg{txO NIfZS5IzPCCq MVfEc5dvemWpdXzheIlwdiCxZjDzeZJ3cX[rbjDlfJBz\XO|aX;uJIlvKGi3bXHuJGxPS0GSIHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ M{DYSFIzQDN{M{G2
HUVEC M3XZdWZ2dmO2aX;uJIF{e2G7 MWCxNE0zPSEQvF2= NWr6doJDOTZiaB?= Mm[0TY5pcWKrdHnvckBw\iCWTl\hcJBp[S2|dHnteYxifGWmIFnDRW0uOSCvUl7BJIV5eHKnc4Ppc44hcW5iSGXWSWMh[XRiMUCgeI8hOjVidV2gdJJmfHKnYYTl[EBnd3JiMU[gbJJ{KGKnZn;y[UBVVk[jbIDoZUBkcGGubHXu[4UhdWWjc4Xy[YQh[W[2ZYKgOkBpenNiYomgVnQuWEOUIHHuZYx6e2m| NFnWb4szOjB{NkSxNC=>
HUVEC M1XiWmZ2dmO2aX;uJIF{e2G7 MkHtNVAuOjVizszN NGDGWFk{OCCvaX6= M17P[GlvcGmkaYTpc44hd2ZiVF7GZYxxcGFvc4TpcZVt[XSnZDDoeY1idiCLQ1HNMVEheHKxbX;0[ZIh[WO2aY\peJkh\XiycnXzd4VlKGmwIFjVWmVEKGG|c3Xzd4VlKGG|IHLleIEu\2GuYXP0c5Nq\GG|ZTDhZ5Rqfmm2eTDheEAyOCC2bzCyOUB2VSCycnX0doVifGWmIH\vdkA{OCCvaX7zJIJm\m:{ZTDUUmZidHCqYTDjbIFtdGWwZ3WgcYVie3W{ZXSgZYZ1\XJiNTDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5 NXOwTWR6OjJyMk[0NVA>
human H1299 cells NYXwXldRTnWwY4Tpc44h[XO|YYm= MVywMlEuOzBizszN MUCyOEBp NYHndXFbTG:5bjDy[Yd2dGG2aX;uJI9nKGOLQWCyJIV5eHKnc4Ppc44hcW5iaIXtZY4hUDF{OUmgZ4VtdHNiYYSgNE4yKHSxIEOwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MV2yNlYzOjB4OR?=
human H1299 cells MoLTSpVv[3Srb36gZZN{[Xl? M2Ll[|AvOS1|MDFOwG0> NETRfnAzPCCq NWPreodmTG:5bjDy[Yd2dGG2aX;uJI9nKGOLQWCyJIV5eHKnc4Ppc44hcW5iaIXtZY4hUDF{OUmgZ4VtdHNiYYSgNE4yKHSxIEOwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXNiaX6gdJJme2WwY3Wgc4YhOTByIIXnM41tKFSUQVnMJIFv\CCSSUPLJIlvcGmkaYTvdkBNYTJ7NECwNi=> MUKyNlYzOjB4OR?=
human H1299 cells Mn;DSpVv[3Srb36gZZN{[Xl? MkH6NE4yNTNyIN88US=> NITTVnIzPCCq MnO1TY5lfWO2aX;uJI9nKESUNTDlfJBz\XO|aX;uJIlvKGi3bXHuJGgyOjl7IHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NWja[|g6OjJ4MkKwOlk>
human H1299 cells MXvGeY5kfGmxbjDhd5NigQ>? MmW1NE4yNTNyIN88US=> MkG5NlQhcA>? Mn[5TY5lfWO2aX;uJI9nKEqQSz3t[YRq[XSnZDDDTG9RKGW6cILld5Nqd25iaX6gbJVu[W5iSEGyPVkh[2WubIOgZZQhOC5zIITvJFMxKHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= NID5WWszOjZ{MkC2PS=>
HEK293 cells NX\lR5dJTnWwY4Tpc44h[XO|YYm= M1e0SFEvPSCq M165TmRqe3CuYXPlcYVvfCCxZjDbN2heVFOGIH\yc40hcHWvYX6gOWhVPiC{ZXPldJRweiCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KGGodHXyJFEvPSCqcoOgZpkhdGmzdXnkJJNkcW62aXzsZZRqd25iY3;1cpRqdmd? M1TEclIzPTN5MUWz
human U251HRE cells NU\UcmFqTnWwY4Tpc44h[XO|YYm= Ml;QTY5pcWKrdHnvckBw\iCqeYDvfIliNWmwZIXj[YQhUEmIMTDhZ5RqfmG2aX;uJIlvKGi3bXHuJHUzPTGKUlWgZ4VtdHNiYomgZ4VtdCCkYYPl[EBz\XCxcoTldkBo\W6nIHHzd4F6 M3nlXVE5PTBzNkCx
human HCT116 cells MX7GeY5kfGmxbjDhd5NigQ>? M2nnTFExKM7:TR?= MnjrTY5pcWKrdHnvckBw\iCDa4Sg[ZhxemW|c3nvckBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYSgNVAhfU1iYomgbY1ufW6xYnzveEBidmGueYPpdy=> M2\VXFIzOjF{N{Kx
Sf9 cells M{S3R4ZtfW:{ZYPj[Y51KHCxbHHybZpifGmxbjDhd5NigQ>? M2XiWmlvcGmkaYTpc44hd2ZiaIXtZY4hWEl|S3fhcY1iKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZpkh\my3b4Lld4NmdnRicH;sZZJqgmG2aX;uJIF{e2G7 MmPvNlEyOjF4M{G=
human HCT116 cells MlO4VJJwdGmoZYLheIlwdiCjc4PhfS=> NFfCTmI4OiCq MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD13MT64NkDPxE1w MV:yOVY6Ozd6Nx?=
human HCT116 cells M3K0OGN6fG:2b4jpZ:Kh[XO|YYm= M{XHVVczKGh? MoTXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9OVYvODFizszNMi=> MoDlNlE6PDV{NUC=
human PC3 cells NILr[GVEgXSxdH;4bYPDqGG|c3H5 NGTQWGE4OiCq NVrlVnhbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9OlEvOzVizszNMi=> M{LTfFIzPDhyOEWx
human HuH7 cells NIjUfW1Rem:uaX\ldoF1cW:wIHHzd4F6 MXK3NkBp M{O0PWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSIXIO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD14Nz6xPEDPxE1w NV[xcppMOjV4OUO3PFc>
human A549 cells MYTQdo9tcW[ncnH0bY9vKGG|c3H5 NGnZXoU4OiCq M2jWTGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD16Mj6zNkDPxE1w NGPEUoYzPTZ7M{e4Oy=>
human A549 cells NUHCTFF[S3m2b4TvfIlkyqCjc4PhfS=> M{Tre|czKGh? NX3LdFcyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6 MXiyNlQ5ODh3MR?=
human PC3 cells NF3QbHpRem:uaX\ldoF1cW:wIHHzd4F6 NV;sWpJQOjVizszN MlOwNVIxKGh? NILhe5RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDheEAzPSC3TTDh[pRmeiBzMkCgbJJ{KGK7IF3UWEBie3OjeTDy[YxifGm4ZTD0c{BFVVOR NGKzb24yPjZ6MEG1PS=>
human H460 cells M36w[GZ2dmO2aX;uJIF{e2G7 M1LMdVMxKM7:TR?= NG\IdoZKdmirYnn0bY9vKG:oIGDJN2shcW5iaIXtZY4hUDR4MDDj[YxteyCjc4Pld5Nm\CCjczDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFOncjC0O|MhfXBidH:gN|AhfU1? NEfWOXcyQDVyMU[wNS=>
human IGROV1 cells NXPUc|Y6TnWwY4Tpc44h[XO|YYm= MV[yOEBp NVX2c4NES2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hUUeUT2[xJINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNUBxcGG|ZTDheEAyKG[xbHSgTWM2OCCjZoTldkAzPCCqcoOgZpkh\myxdzDjfZRwdWW2com= MV2yNVIyPjF3MR?=
human IGROV1 cells M1q1S2Z2dmO2aX;uJIF{e2G7 M12zeVI1KGh? M{LjUmNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGlIWk:YMTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{GgdIhie2ViYYSgOUBnd2ymIFnDOVAh[W[2ZYKgNlQhcHK|IHL5JIZtd3diY4n0c41mfHK7 M1X4[|IyOjF4MUWx
human H4 cells NID1N4tHfW6ldHnvckBie3OjeR?= NV3DTHhzOiCq NX3jPIxiTGWlcnXhd4UhcW5iRmnWSU1TTlBtII\ld4lkdGViaX70[Y5{cXS7IIDldkBk\WyuIHnuJIh2dWGwIFi0JINmdGy|IHHmeIVzKDJiaILzJJJmdGG2aY\lJJRwKGOxboTyc4w> NIXrUVUyQDB{NEW4OC=>
human MGC803 cells MXfGeY5kfGmxbjDhd5NigQ>? MkHhNlUh|ryP NYrKb2F{PDhiaB?= NWjINZJoS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hVUeFOECzJINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNk9OKHCqYYPlJIF1KDJ3IIXNJIFnfGW{IES4JIhzeyC3c3nu[{Bxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIFnfGW{IES4JIhzeyCkeTDmcI94KGO7dH;t[ZRmeiC{ZXzheIl3\SC2bzDjc451em:u M{fKbVI1OTF7OE[5

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
E-cadherin / p-Akt / Akt; 

PubMed: 29731993     


Immunoblot analysis of E-cadherin, P-AKT, and AKT in SNU-C5/5-FU cells treated with LY294002 (20 μM).

beta-catenin / p-GSK3β / Cyclin D1; 

PubMed: 29731993     


Immunoblot analysis of P-AKT, AKT, β-catenin, P-GSK-3β, GSK-3β, and cyclin D1 in SNU-C5/5-FU cells treated with LY294002 (20 μM).

Bcl-xl / Bax / caspase3 / cleaved caspase-3; 

PubMed: 25344912     


Four esophageal cancer cell lines were treated with different concentrations of LY294002 for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved caspase-3.

p-p70S6K (T389) / p-GSK3β(S9) / pERK / Vinculin; 

PubMed: 23251002     


HT29, Colo205, and RKO cells were treated for 2 h with PLX4720, LY294002 or their combination at indicated concentrations. Cell lysates were subjected to western blot analysis with antibodies against phosphorylated or total forms of AKT or ERK1/2, and antibodies against p-P70S6K, pGSK3β or vinculin.

pPKB-S473; 

PubMed: 20649566     


Typical Western blot showing that basal pPKB-S473 was reduced by increasing concentrations of LY294002 (upper panel). Pre-incubating 10 µM of the MEK-1/2 inhibitor U0126 induced pPKB–S473 levels which were reduced when rising concentrations of LY294002 were added. A full suppression of pPKB–S473 below the detection limit was seen at 30 µM PI3K inhibitor (10 µM U0126 + 30 µM LY294002). β-Actin immunoreaction served as loading control.

29731993 25344912 23251002 20649566
Growth inhibition assay
Cell viability; 

PubMed: 25344912     


MTT assay was used to determine the effects of different concentrations of LY294002 on viability of esophageal cancer cells lines KYSE150, HKESC-1, KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.

25344912
Immunofluorescence
α-SMA / CD31; 

PubMed: 27671604     


Immunofluorescence analysis for the expression levels of CD31 and α-SMA in Control, LY294002, As2O3 and As2O3 + LY294002 groups. Scale bar = 30 μm. (in HAECs).

E-cadherin / beta-catenin; 

PubMed: 29731993     


The localization of E-cadherin and β-catenin were confirmed by confocal microscopy. Scale bars, 20 μm.

COX-2 / p-NFκB; 

PubMed: 29731993     


The localization of Cox-2 and P-NF-κB was confirmed by confocal microscopy. Scale bars, 20 μm.

FOXO3a; 

PubMed: 18388194     


C2C12 cells were plated into two-well chamber sliders for 24 h and then treated with 20 μm LY294002 or the same amount of vehicle (ethanol) for 16 h. Cells were fixed and FOXO3a was stained. LY294002 treatment activates FOXO3a and leads its translocation into the nucleus.

27671604 29731993 18388194
ELISA
IL-10 / IL-1β / TNFα / IL-6; 

PubMed: 22208359     


Microglial cells were pre-treated with LY294002 for 1 h and then stimulated with LPS (100 ng/ml) or PIC (10 μg/ml) for 16 h. ELISA were performed. All values were normalized to those obtained in cultures stimulated with LPS or PIC without LY294002 (= 1). At least 3 cases were analyzed for each experiment, and statistics were performed using t-test comparing values with vs. without LY294002.

22208359
体内研究 体内，LY294002也抑制肿瘤生长和诱导凋亡，尤其作用于LoVo肿瘤, 因此作用于鼠癌性腹膜炎模型具有明显药效。[2] LY294002明显抑制卵巢癌生长和腹水形成。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：

[4]
+ 展开

激酶实验:

使用重组酶和1 μM ATP，通过辐射实验测定LY294002对PI3K的抑制效果。室温下(24oC)进行激酶反应1小时，然后加入PBS终止反应。通过剂量反应曲线测定IC50值。通过激酶选择性筛选来抑制CK2和GSK3β。加入10 μM ATP，测定LY294002作用于一组激酶的效果。
细胞实验：

[2]
+ 展开
  • Cell lines: 结肠癌细胞系： DLD-1, LoVo, HCT15, 和Colo205
  • Concentrations: 0-50 μM
  • Incubation Time: 0-48小时
  • Method:

    1×105个细胞(每孔100 μL)接种在96孔板上。加入LY294002，重复加三次，在37oC下培养0-48小时。处理后, 10 μL Premix WST-1 加到每孔中,然后在37oC下温育60分钟,然后用微型计数板在450nm处测定吸光值。


    (Only for Reference)
动物实验：

[3]
+ 展开
  • Animal Models: 腹腔注射OVCAR-3细胞的无胸腺裸鼠(5-7周大)
  • Formulation: 溶解在DMSO和0.25 ml PBS中
  • Dosages: 0-100 mg/kg
  • Administration: 每天腹腔注射，持续3周
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 36 mg/mL (117.13 mM)
Ethanol 21 mg/mL (68.32 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
 5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 307.34
化学式

C19H17NO3
CAS号 154447-36-6
储存条件 powder
in solvent
别名 SF 1101, NSC 697286

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02337309 Terminated Neuroblastoma New Approaches to Neuroblastoma Therapy Consortium|SignalRX Pharmaceuticals Inc.|University of Southern California July 9 2015 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    I want to buy a inhibitor that can inactivates Akt/PI3K. I notice the protocol of LY294002 (catalog no. s1105) says it will inactivates Akt/PKB. Is LY294002 available for Akt/PI3K inhibition?

  • 回答：

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively. It can inhibit PI3K/AKT. PKB is the alternative name of AKT.

  • 问题 2：

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • 回答：

    It can be dissolved in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml clearly, and the concentration of DMSO is safe for in vivo experiments.

Selleck产品目录册

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

  • Taselisib (GDC 0032) New

    Taselisib (GDC 0032)是一种有效，下一代的β亚型PI3K抑制剂，作用于PI3Kα/δ/γ， IC50分别为0.29 nM/0.12 nM/0.97nM，比作用于PI3Kβ选择性高10倍以上。

  • Pilaralisib (XL147) New

    Pilaralisib (XL147)是一种选择性的可逆I型PI3K抑制剂，作用于PI3Kα/δ/γ，在无细胞试验中IC50为 39 nM/36 nM/23 nM，对PI3Kβ作用较低。Phase 1/2。

  • GNE-317 New

    GNE-317 是一种有效的，大脑渗透性 PI3K 抑制剂。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA)是一种选择性PI3K抑制剂，作用于Vps34和PI3Kγ，在 HeLa细胞中IC50分别为25 μM和60 μM；永久性抑制I型PI3K，但对III型PI3K的抑制是短暂的，也会阻断自噬体的形成。现配现用（加热助溶）。

  • Idelalisib (CAL-101, GS-1101)

    Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂，在无细胞试验中IC50为 2.5 nM；对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍，对p110δ的选择性是对 C2β，hVPS34，DNA-PK 和 mTOR的400到4000倍。

    Features:Calistoga 暗示 CAL-101治疗血液恶性肿瘤可能有更广泛的应用价值。

  • Wortmannin

    Wortmannin是一种首次命名的PI3K抑制剂，在无细胞试验中IC50为3 nM，对 PI3K 家族的选择性较低。也会抑制自噬体的形成，并有效抑制DNA-PK/ATM，在无细胞试验中IC50为16 nM和150 nM。

  • Dactolisib (BEZ235, NVP-BEZ235)

    Dactolisib (BEZ235, NVP-BEZ235) 是一种双重ATP竞争性 PI3K 和 mTOR 抑制剂，在无细胞试验中，抑制 p110α/γ/δ/β 和 mTOR(p70S6K) 的 IC50 分别为 4 nM /5 nM /7 nM /75 nM /6 nM。 在 3T3TopBP1-ER 细胞中抑制 ATR，IC50 为 21 nM，而对 Akt 和 PDK1 的抑制作用很弱。Phase 2。

  • Buparlisib (BKM120, NVP-BKM120)

    Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂，在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34，mTOR，DNAPK 的作用效果下降，而对 PI4Kβ几乎没有活性。Phase 2。

    Features:BKM120是可用于口服的生物有效的PI3K抑制剂。

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941) 是一种有效的PI3Kα/δ抑制剂，在无细胞试验中IC50为 3 nM，对p110β (11倍)和p110γ (25倍)具有适度的选择性。Phase 2。

  • Alpelisib (BYL719)

    Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂，在无细胞试验中IC50为 5 nM，对PI3Kβ/γ/δ具有极弱的作用。Phase 2。

Tags: 购买LY294002 | LY294002供应商 | 采购LY294002 | LY294002价格 | LY294002生产 | 订购LY294002 | LY294002代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID